Inovalon Reports Second Quarter 2019 Results

    NEXT STORY
    Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers
    PREV STORY
    MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

    Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin ...

    author_avatar
    NASDAQ Market News

    Merit Medical Systems to Announce Third Quarter Results on October 28, 2020 and Host “Foundations for Growth” Investor Call on November 10, 2020

    author_avatar
    NASDAQ Market News

    Medical Mask Market to Grow at 8.5% CAGR and Touch USD 2.15 Billion by 2027; Driven by Growing Investments in Product Manufacturing, says Fortune Business Insights™

    author_avatar
    NASDAQ Market News